Point of Care Diagnostics/Testing Market Research Report - Global Forecast till 2027

Point of Care Diagnostics/Testing Market: By Product (Glucose Monitoring, Cardiometabolic Monitoring, Infectious Disease Testing, Coagulation Monitoring, Pregnancy & Fertility Testing, Hematology Testing, Cancer/Tumor Marker Testing, Urinalysis Testing, Cholesterol, Drugs-of-Abuse Testing), By End User (Hospitals & Clinics, Diagnostic Centers, Homecare/Self Testing), By Mode of Purchase (OTC, Prescription-based), By Platform (Immunoassays, Molecular Diagnostics, Dipsticks), and Region (North America, Europe, Asia-Pacific, Rest of the World)—Forecast to 2027

ID: MRFR/HC/9161-HCR | August 2021 | Region: Global | 120 pages

Market Forecast


The global point of care diagnostics/testing market is expected to cross ~USD 36,740.3 million by 2027 at a CAGR of ~11.6% during the forecast period of 2021-2027.


Market Overview:


Point of care diagnostics/testing is a health analysis that is carried out near the patient and does not include any laboratory setting. Point of Care (POC) testing is also called near-patient testing, bedside testing, mobile testing, remote testing, and rapid diagnosis. The procedure is used to diagnose infectious diseases in sites with limited healthcare infrastructure. POC testing offers instant diagnostic results minimizing the number of patient visits, increasing diagnosis efficiency, and enabling timely treatment. In addition, it streamlines the testing process for the healthcare personnel and provides effective results. The POC testing devices are utilized to carry out diagnostic tests such as blood glucose level tests, levels of blood gases, analysis of electrolytes and enzymes, and tests for signs of infection. These devices run on different principles, including Lateral-Flow Immunochromatographic Assay (LFIA), molecular, and biochemical. Furthermore, portability, convenience, connectivity, speed, and result assurance areaugmenting the demand for POC testing products.


With an increasing number of chronic disorderssuch as diabetes across the globe and a limited number of healthcare facilities in the developing economies, the introduction of portable POC devices supporting government policies is augmenting the POC diagnostics/testing market. Moreover, the market players are offering digital and wireless POC solutions to increase the efficiency and accuracy of the diagnosis. The new era POCs are connected with smartphones and display the analysis and test results on the connected device. Additionally, this advancement has allowed the medical practitioners and the patients to manage the diagnosed data and maintain the records in an electrical format. These factors are driving the demand for POC diagnostic/testing products throughout the globe.


COVID-19 Analysis


The pandemic outbreak ceased the operations of all the sectors throughout the globe. The healthcare industry was hit hard during the initial phase of the lockdown. Medical stocks were piled up in large numbers, and the number of the produced goods rose as the supply chain within and across borders was highly affected due to the implementation of the safety guidelines. However, after the decline in the number of affected cases, the regulatory authorities allowed the limited mobility and manufacturing of the essential products. The relaxation in the guidelines accelerated the demand for healthcare products supporting the point of care diagnostics/testing market.


During the pandemic, the market players invested huge amounts in the development of rapid tests to diagnose COVID-19. According to WHO, in September 2020, the industry players partnered to develop 120 million economic antigen-based rapid diagnostic POC tests for developing countries. Bill & Melinda Gates Foundation (US), SD BioSensor Inc. (South Korea), and Abbott Laboratories (US) signed an agreement to offer the POC test products for a maximum price of USD 5. The Global Fund allotted USD 50 million to enable low- and middle-income countries (LMICs)to buy the diagnostic test product. Moreover, in September 2020 FDA authorized the POC antibody test for COVID-19 that will allow people to understand their health status and let them know whether the virus has infected them or not. Furthermore, the regulatory authorities updated their guidelines related to the SARS-CoV-2 pointof care and rapid testing. These supportive factors propelled the market growth and are expected to augment in the forecast period.


Market Dynamics


Drivers


  • Increasing demand for COVID-19 POC test kits


Increasing cases of coronavirus across the globe have augmented the demand for self-diagnosing kits and devices. Restricted mobility has accelerated the demand for POCs for diagnosing different variants of coronavirus. In addition, international healthcare authorities such as WHO)have shared guidelines related to the COVID-POCs to increase the self-diagnosis of the disease, further preventing the spread of the fatal virus. Moreover, a few market players are launching new products to gain a competitive edge over their competitors. For instance, in March 2020,Abbott Laboratories (US) launched a molecular pointofcare test to detect coronavirus within 5 minutes. The company delivered 50,000 tests every day. Moreover, the increasing population diagnosed with chronic diseases is driving the POC diagnostic/testing market.



  • Risingnumber of chronic disease cases across the globe

  • Growing demand for AI integrated POCs for real-time diagnostics


Market Restraints


  • Stringent regulatory policies


The healthcare regulation varies regionally, which is one of the major challenges faced by device manufacturers to deploy their devices in compliance with the regional authorities. The multi-layered regulations established by the international governing authorities such as FDA and CLIA are restraining the market growth of the POC manufacturers and creating a regulatory barrier in the promotion and sales of their products. In addition, the healthcare device manufacturers have to submit the performance data of their products stating the pros and cons of the product on the tested individuals. These authorities verify the accessibility and challenges of the POCrelated to the product administration. These actors are hindering the market growth of the POC diagnostics/testing market across the globe.



  • Technology Analysis


Point of care testing is gaining importance due to the efficient and accurate diagnostic results. The POC testing products are integrated with new technologies such as biosensors and artificial intelligence that offer real-time remote monitoring. The introduction of biosensors in the POC testing devices increases the potential of rapid medical diagnosis. The biosensors are available specifically as chip-based biosensors and paper-based biosensors with the ability to detect antibodies, antigens, or nucleic acids using samples such as blood, saliva, and sputum. Moreover, the integration of artificial intelligence technology in POC testing devices aims to decrease the testing time and increase the accuracy of the tests.

Additionally, the deployment of AI technology will store the test results for further reference. The device aims to analyze the results and suggest the preventivemeasures that the patients should adopt to maintain their physical and mental health. These technologies are driving the point of care diagnostics/testing market and are projected to propagate rapidly in the forecast timeline.


Segment Overview


By Product



  • Glucose Monitoring: It is a type of device in which glucose concentrationin the blood is measuredusing a lancet, meter, or any other device.

  • Cardiometabolic Monitoring: It is a type of monitoring device in which risk related to cardiovascular functions such as blood pressure, blood gas,blood fat, LDL (low-density lipoprotein) levels, etc., is monitored.

  • Infectious Disease Testing: It is a type of device which detects disorders caused by organisms such as viruses, bacteria, and fungi.

  • Coagulation Monitoring: It is a type of device in which blood clotting ability is tested. It will provide significant analysis to the doctors about the proper deployment of the clotting factor in the bleeding area.

  • Pregnancy & Fertility Testing: It is a type of device that tests the ability to conceive naturally and the presence of any kind of sexually transmitted diseases in both men and women.

  • Hematology Testing:These devices carry out blood tests to evaluate complete blood count, protein levels, infection, inflammation, blood-clotting disorders, anemia, and leukemia.

  • Cancer/Tumor Marker Testing:It is a device in which tumor markers in the blood, tissue, urine, and other body fluids are monitored. The device tracks the protein and other substances that are formed in response to the tumor cells.

  • Urinalysis Testing: This device diagnoses urinary tract infections, detects kidney disorders, diabetes levels, liver problems, and other metabolic functions.

  • Cholesterol: It is a type of device that measures high-density and low-density proteins and certain fats in the blood.

  • Drugs-of-Abuse Testing: It is a type of device that measures illegal substances for non-medical reasons in urine, saliva, blood, hair, and sweat.


By End User


  • Hospitals & Clinics Hospitals & Clinics are the organizations that offer medical and surgical treatment to the wounded.

  • Diagnostic Centers It is a place where diagnostic services are offered to the general public and medical practitioners.

  • Homecare/Self Testing It is healthcare support offered by the professional caregiver for health services to patients in their homes.


By Mode of Purchase


  • OTC Testing Products It is a type of test that does not require a prescription and isindependent of healthcare settings.

  • Prescription-based testing products It is a type of test that is carried out based on the prescription by the doctor.


By Platform


  • Immunoassays It is a platformused to measure particular proteins and supplementary substances through their antigen and antibody properties.

  • Molecular Diagnostics It is a platform used to identify disease using molecules such as DNA, RNA, tissue, fluid, and proteins.

  • Dipsticks It is a chemical integrated sensitive strip of paper used to detect glucose, protein, and other components in urine.


Regional Analysis

North America


Increasing demand for remote diagnostics is driving the North American point of care diagnostics/testing market
North America held the largest point of care diagnostics/testing market share in 2020, owing to the increasing number of market players across the region, acquisition of the market players by the healthcare giants, and supportive government policies. The healthcare product providers are involved in the merger and acquisition of the existing market players to expand their product availability across the region. For instance, in January 2021, Heska Corporation (US) acquired Lacuna Diagnostics (US), a company that provides digital cytology point of care and telemedicine service. This acquisition enables the company to expand its product pipeline. Moreover, the market players are adopting business strategies such as the launch of new products, R&D activities, and collaborative product development for business growth.

Asia-Pacific


  • Advancement in healthcare infrastructure is fueling the Asia-Pacific point of care diagnostics/testing market

  • The Asia-Pacific point of care diagnostics/testing market is projected to be the fastest-growing regional market due to limited availability of the healthcare staff, diversified manufacturing facilities, changing demographics, and shifting consumer healthcare expectations. Moreover, other factors supporting the point of care diagnostics/testing market include reassuring government guidelines, significant funding by industry players, and innovation of technically advanced products.


Competitive Landscape


  • Siemens (Germany) is one of the prominent players in the point of care testing market. The company offers a wide range of products to detect medical conditions such as acute respiratory distress, acute kidney injury, sepsis/septic shock, and acute respiratory failure. Under the blood gas systems, the company offers products such as EPOC blood analysis system with the NXS host, Rapidlab 1200 systems, rapidpoint 500e blood gas system, and blood gas syringes and capillaries. In addition, under the diabetes testing equipment, the company provides a DCA vantage analyzer, DCA HbA1c reagent kit, and DCA microalbumin/creatinine urine test kit. Moreover, the CLINITEK analyzer and urine chemistry analyzer are the urinalysis testing products offered by the company.

  • The industry players are consistently evolving with the changing healthcare needs. These market competitors are adopting various business strategies to augment their market growth. The companies are capitalizing on the new technologies and are advancing their R&D facilities to develop new products, further driving the point of care diagnostics/testing market. Additionally, the industry players are involved in contractual agreements, acquisitions and mergers, product innovations, increasing investments, and partnering with other regional or local players to expand their global footprint.


List of Key Companies Covered in this Report:


  • Abbott Laboratories (US)

  • Siemens Healthineers GmbH (Germany)

  • Chembio Diagnostics, Inc.(US)

  • Hoffmann-La Roche Ltd (Switzerland)

  • Johnson & Johnson Services, Inc. (US)

  • Becton, Dickinson and Company (US)

  • Danaher Corporation (US)

  • PTS Diagnostics (US)

  • Nova Biomedical (US)

  • QuidelCorporation (US)

  • Sekisui Diagnostics (US)

  • Trinity Biotech (Ireland)

  • , Ltd.(China)

  • Instrumentation Laboratory Company (Werfen) (US)

  • EKF Diagnostics Holdings plc (UK)


Recent Developments


  • In June 2021,DCN Dx(US) acquired the pointofcare diagnostics development company PortaScience Inc. (US). This acquisition will expand the point of care product portfolio of the company.

  • In April 2021,the Indian Institute of Technology Kharagpur (India), an Indian engineering institute,launched a nucleic acid-based pointof care diagnostic devicefor COVID-19 diagnosis.

  • In April 2021,LumiraDx (US), a next-generation point of care diagnostics testing company,announced its merger with CA Healthcare Acquisition (CAHC) (US)in a deal worth USD 5 billion.

  • In March 2021, MatMaCorp (US) launched MYRTA, a handheld real-time POCPCR device for molecular diagnostics.

  • In March 2020, Abbott(US) launched the fastest available molecular pointofcare test to detect the coronavirus in less than 5 minutes.


Report Overview


  • The study covers the existing short-term and long-term market effects andhelps decision-makers to draught short-term and long-term plans for businesses by region. The report covers major regions in North America, Europe, Asia-Pacific, and the Rest of the World. The report analyzes market drivers, restraints, opportunities, challenges, Porter’s Five Forces, value chain, and impact of COVID on the market.


Scope of the Report & Segmentation

By Product



  • Glucose Monitoring

    • Strips

    • Meters

    • Lancets



  • Cardiometabolic Monitoring

    • Cardiac Marker Testing Products

    • Blood Gas/Electrolyte Testing Products

    • HbA1c Testing Products



  • Infectious Disease Testing

    • HIV Testing  

    • Respiratory Infection Testing

    • Hepatitis Testing

    • Sexually Transmitted Disease Testing

    • Others



  • Coagulation Monitoring

    • PT/INR Testing

    • ACT/APTT Testing



  • Pregnancy & Fertility Testing

  • Hematology Testing

  • Cancer/Tumor Marker Testing

  • Urinalysis Testing

  • Cholesterol

  • Drugs-of-Abuse Testing

  • Others


By End User


  • Hospitals & Clinics

  • Diagnostic Centers

  • Homecare/Self Testing

  • Others


By Mode of Purchase


  • OTC Testing Products

  • Prescription-based testing products


By Platform


  • Immunoassays

  • Molecular Diagnostics

  • Dipsticks

  • Others



TABLE OF CONTENTS

1. REPORT PROLOGUE

2. MARKET INTRODUCTION

2.1. Definition

2.2. Scope of the Study

2.2.1. Research Objective

2.2.2. Assumptions

2.2.3. Limitations

3. RESEARCH METHODOLOGY

3.1. Overview

3.2. Data Mining

3.3. Secondary Research

3.4. Primary Research

3.4.1. Primary Interviews and Information Gathering Process

3.4.2. Breakdown of Primary Respondents

3.5. Forecasting Cellulite Type

3.6. Market Size Estimation

3.6.1. Bottom-Up Approach

3.6.2. Top-Down Approach

3.7. Data Triangulation

3.8. Validation

4. MARKET DYNAMICS

4.1. Overview

4.2. Drivers

4.3. Restraints

4.4. Opportunities

5. MARKET FACTOR ANALYSIS

5.1. Porter’s Five Forces Analysis

5.1.1. Bargaining Power of Suppliers

5.1.2. Bargaining Power of Buyers

5.1.3. Threat of New Entrants

5.1.4. Threat of Substitutes

5.1.5. Intensity of Rivalry

5.2. Value Chain Analysis

5.3. COVID-19 Impact Analysis

5.3.1. Market Impact Analysis

5.3.2. Impact on Supply Chain

5.3.3. Regional Impact

5.3.4. Opportunity and Threat Analysis

6. GLOBAL POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY PRODUCT

6.1. Overview

6.2. Glucose Monitoring

Market Estimates & Forecast, by Region, 2018–2027

Market Estimates & Forecast, by Country, 2018–2027

6.2.1. Strips

Market Estimates & Forecast, by Region, 2018–2027

Market Estimates & Forecast, by Country, 2018–2027

6.2.2. Meters

Market Estimates & Forecast, by Region, 2018–2027

Market Estimates & Forecast, by Country, 2018–2027

6.2.3. Lancets

Market Estimates & Forecast, by Region, 2018–2027

Market Estimates & Forecast, by Country, 2018–2027

6.3. Cardiometabolic Monitoring

Market Estimates & Forecast, by Region, 2018–2027

Market Estimates & Forecast, by Country, 2018–2027

6.3.1. Cardiac Marker Testing Products

Market Estimates & Forecast, by Region, 2018–2027

Market Estimates & Forecast, by Country, 2018–2027

6.3.2. Blood Gas/Electrolyte Testing Products

Market Estimates & Forecast, by Region, 2018–2027

Market Estimates & Forecast, by Country, 2018–2027

6.3.3. HbA1c Testing Products

Market Estimates & Forecast, by Region, 2018–2027

Market Estimates & Forecast, by Country, 2018–2027

6.4. Infectious Disease Testing

Market Estimates & Forecast, by Region, 2018–2027

Market Estimates & Forecast, by Country, 2018–2027

6.4.1. HIV Testing

Market Estimates & Forecast, by Region, 2018–2027

Market Estimates & Forecast, by Country, 2018–2027

6.4.2. Respiratory Infection Testing

Market Estimates & Forecast, by Region, 2018–2027

Market Estimates & Forecast, by Country, 2018–2027

6.4.3. Hepatitis Testing

Market Estimates & Forecast, by Region, 2018–2027

Market Estimates & Forecast, by Country, 2018–2027

6.4.4. Sexually Transmitted Disease Testing

Market Estimates & Forecast, by Region, 2018–2027

Market Estimates & Forecast, by Country, 2018–2027

6.4.5. Others

Market Estimates & Forecast, by Region, 2018–2027

Market Estimates & Forecast, by Country, 2018–2027

6.5. Coagulation Monitoring

Market Estimates & Forecast, by Region, 2018–2027

Market Estimates & Forecast, by Country, 2018–2027

6.5.1. PT/INR Testing

Market Estimates & Forecast, by Region, 2018–2027

Market Estimates & Forecast, by Country, 2018–2027

6.5.2. ACT/APTT Testing

Market Estimates & Forecast, by Region, 2018–2027

Market Estimates & Forecast, by Country, 2018–2027

6.6. Pregnancy & Fertility Testing

Market Estimates & Forecast, by Region, 2018–2027

Market Estimates & Forecast, by Country, 2018–2027

6.7. Hematology Testing

Market Estimates & Forecast, by Region, 2018–2027

Market Estimates & Forecast, by Country, 2018–2027

6.8. Cancer/Tumor Marker Testing

Market Estimates & Forecast, by Region, 2018–2027

Market Estimates & Forecast, by Country, 2018–2027

6.9. Urinalysis Testing

Market Estimates & Forecast, by Region, 2018–2027

Market Estimates & Forecast, by Country, 2018–2027

6.10. Cholesterol

Market Estimates & Forecast, by Region, 2018–2027

Market Estimates & Forecast, by Country, 2018–2027

6.11. Drugs-of-Abuse Testing

Market Estimates & Forecast, by Region, 2018–2027

Market Estimates & Forecast, by Country, 2018–2027

6.12. Others

Market Estimates & Forecast, by Region, 2018–2027

Market Estimates & Forecast, by Country, 2018–2027

7. GLOBAL POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY END USER

7.1. Overview

7.2. Hospitals & Clinics

Market Estimates & Forecast, by Region, 2018–2027

Market Estimates & Forecast, by Country, 2018–2027

7.3. Diagnostic Centers

Market Estimates & Forecast, by Region, 2018–2027

Market Estimates & Forecast, by Country, 2018–2027

7.4. Homecare/Self Testing

Market Estimates & Forecast, by Region, 2018–2027

Market Estimates & Forecast, by Country, 2018–2027

7.5. Others

Market Estimates & Forecast, by Region, 2018–2027

Market Estimates & Forecast, by Country, 2018–2027

8. GLOBAL POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY MODE OF PURCHASE

8.1. Overview

8.2. OTC Testing Products

Market Estimates & Forecast, by Region, 2018–2027

Market Estimates & Forecast, by Country, 2018–2027

8.3. Prescription-based testing products

Market Estimates & Forecast, by Region, 2018–2027

Market Estimates & Forecast, by Country, 2018–2027

9. GLOBAL POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY PLATFORM

9.1. Overview

9.2. Immunoassays

Market Estimates & Forecast, by Region, 2018–2027

Market Estimates & Forecast, by Country, 2018–2027

9.3. Dipsticks

Market Estimates & Forecast, by Region, 2018–2027

Market Estimates & Forecast, by Country, 2018–2027

9.4. Molecular Diagnostics

Market Estimates & Forecast, by Region, 2018–2027

Market Estimates & Forecast, by Country, 2018–2027

9.5. Others

Market Estimates & Forecast, by Region, 2018–2027

Market Estimates & Forecast, by Country, 2018–2027

10. GLOBAL POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY REGION

10.1. Overview

10.2. North America

10.2.1. US

10.2.2. Canada

10.3. Europe

10.3.1. Germany

10.3.2. France

10.3.3. UK

10.3.4. Italy

10.3.5. Spain

10.3.6. Rest of Europe

10.4. Asia-Pacific

10.4.1. China

10.4.2. India

10.4.3. Japan

10.4.4. South Korea

10.4.5. Australia

10.4.6. Rest of Asia-Pacific

10.5. Rest of the World

10.5.1. Middle East

10.5.2. Africa

10.5.3. Latin America

11. COMPANY LANDSCAPE

11.1. Overview

11.2. Competitive Analysis

11.3. Market Share Analysis

11.4. Major Growth Strategy in the Global Point of Care Diagnostics/Testing Market

11.5. Competitive Benchmarking

11.6. Leading Players in Terms of Number of Developments in the Global Point of Care Diagnostics/Testing Market

11.7. Key developments and Growth Strategies

11.7.1. New ProductLaunch/Service Deployment

11.7.2. Merger &Acquisitions

11.7.3. Joint Ventures

11.8. Major Players Financial Matrix

11.8.1. Sales & Operating Income, 2020

11.8.2. Major Players R&D Expenditure, 2020

12. COMPANY PROFILES

12.1. Abbott Laboratories

12.1.1. Company Overview

12.1.2. Product Offered

12.1.3. Financial Overview

12.1.4. Key Developments

12.1.5. SWOT Analysis

12.1.6. Key Strategies

12.2. Siemens Healthineers GmbH

12.2.1. Company Overview

12.2.2. Product Offered

12.2.3. Financial Overview

12.2.4. Key Developments

12.2.5. SWOT Analysis

12.2.6. Key Strategies

12.3. Chembio Diagnostics, Inc.

12.3.1. Company Overview

12.3.2. Product Offered

12.3.3. Financial Overview

12.3.4. Key Developments

12.3.5. SWOT Analysis

12.3.6. Key Strategies

12.4. F. Hoffmann-La Roche Ltd

12.4.1. Company Overview

12.4.2. Product Offered

12.4.3. Financial Overview

12.4.4. Key Developments

12.4.5. SWOT Analysis

12.4.6. Key Strategies

12.5. Johnson & Johnson Services, Inc.

12.5.1. Company Overview

12.5.2. Product Offered

12.5.3. Financial Overview

12.5.4. Key Developments

12.5.5. SWOT Analysis

12.5.6. Key Strategies

12.6. Becton, Dickinson and Company

12.6.1. Company Overview

12.6.2. Product Offered

12.6.3. Financial Overview

12.6.4. Key Developments

12.6.5. SWOT Analysis

12.6.6. Key Strategies

12.7. Danaher Corporation

12.7.1. Company Overview

12.7.2. Product Offered

12.7.3. Financial Overview

12.7.4. Key Developments

12.7.5. SWOT Analysis

12.7.6. Key Strategies

12.8. PTS Diagnostics

12.8.1. Company Overview

12.8.2. Product Offered

12.8.3. Financial Overview

12.8.4. Key Developments

12.8.5. SWOT Analysis

12.8.6. Key Strategies

12.9. Nova Biomedical

12.9.1. Company Overview

12.9.2. Product Offered

12.9.3. Financial Overview

12.9.4. Key Developments

12.9.5. SWOT Analysis

12.9.6. Key Strategies

12.10. Quidel Corporation

12.10.1. Company Overview

12.10.2. Product Offered

12.10.3. Financial Overview

12.10.4. Key Developments

12.10.5. SWOT Analysis

12.10.6. Key Strategies

12.11. Sekisui Diagnostics

12.11.1. Company Overview

12.11.2. Product Offered

12.11.3. Financial Overview

12.11.4. Key Developments

12.11.5. SWOT Analysis

12.11.6. Key Strategies

12.12. Trinity Biotech

12.12.1. Company Overview

12.12.2. Product Offered

12.12.3. Financial Overview

12.12.4. Key Developments

12.12.5. SWOT Analysis

12.12.6. Key Strategies

12.13. AccuBioTech Co., Ltd.

12.13.1. Company Overview

12.13.2. Product Offered

12.13.3. Financial Overview

12.13.4. Key Developments

12.13.5. SWOT Analysis

12.13.6. Key Strategies

12.14. Instrumentation Laboratory Company (Werfen)

12.14.1. Company Overview

12.14.2. Product Offered

12.14.3. Financial Overview

12.14.4. Key Developments

12.14.5. SWOT Analysis

12.14.6. Key Strategies

12.15. EKF Diagnostics Holdings plc

12.15.1. Company Overview

12.15.2. Product Offered

12.15.3. Financial Overview

12.15.4. Key Developments

12.15.5. SWOT Analysis

12.15.6. Key Strategies

13. APPENDIX

13.1. References

13.2. Related Reports

LIST OF TABLES

TABLE 1 GLOBAL POINT OF CARE DIAGNOSTICS/TESTING MARKET SYNOPSIS, 2018–2027

TABLE 2 GLOBAL POINT OF CARE DIAGNOSTICS/TESTING MARKET ESTIMATES &FORECAST, 2018–2027(USD MILLION)

TABLE 3 GLOBAL POINT OF CARE DIAGNOSTICS/TESTING MARKET, BYPRODUCT, 2018–2027 (USD MILLION)

TABLE 4 GLOBAL POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY END USER,2018–2027 (USD MILLION)

TABLE 5 GLOBAL POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY MODE OF PURCHASE, 2018–2027 (USD MILLION)

TABLE 6 GLOBAL POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY PLATFORM, 2018–2027 (USD MILLION)

TABLE 7 NORTH AMERICA OF CARE DIAGNOSTICS/TESTING MARKET, BY PRODUCT, 2018–2027 (USD MILLION)

TABLE 8 NORTH AMERICAPOINT OF CARE DIAGNOSTICS/TESTING MARKET, BY END USER,2018–2027 (USD MILLION)

TABLE 9 NORTH AMERICAPOINT OF CARE DIAGNOSTICS/TESTING MARKET, BY MODE OF PURCHASE, 2018–2027 (USD MILLION)

TABLE 10 NORTH AMERICAPOINT OF CARE DIAGNOSTICS/TESTING MARKET, BY PLATFORM, 2018–2027 (USD MILLION)

TABLE 11 US: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY PRODUCT, 2018–2027 (USD MILLION)

TABLE 12 US POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY END USER, 2018–2027 (USD MILLION)

TABLE 13 US: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY MODE OF PURCHASE, 2018–2027 (USD MILLION)

TABLE 14 US: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY PLATFORM, 2018–2027 (USD MILLION)

TABLE 15 CANADA: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY PRODUCT, 2018–2027 (USD MILLION)

TABLE 16 CANADA POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY END USER, 2018–2027 (USD MILLION)

TABLE 17 CANADA: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY MODE OF PURCHASE, 2018–2027 (USD MILLION)

TABLE 18 CANADA: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY PLATFORM, 2018–2027 (USD MILLION)

TABLE 19 EUROPE: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY PRODUCT, 2018–2027 (USD MILLION)

TABLE 20 EUROPE: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY END USER, 2018–2027 (USD MILLION)

TABLE 21 EUROPE: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY MODE OF PURCHASE, 2018–2027 (USD MILLION)

TABLE 22 EUROPE: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY PLATFORM, 2018–2027 (USD MILLION)

TABLE 23 GERMANY: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY PRODUCT, 2018–2027 (USD MILLION)

TABLE 24 GERMANY: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY END USER, 2018–2027 (USD MILLION)

TABLE 25 GERMANY: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY MODE OF PURCHASE, 2018–2027 (USD MILLION)

TABLE 26 GERMANY: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY PLATFORM, 2018–2027 (USD MILLION)

TABLE 27 FRANCE: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY PRODUCT, 2018–2027 (USD MILLION)

TABLE 28 FRANCE: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY END USER, 2018–2027 (USD MILLION)

TABLE 29 FRANCE: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY MODE OF PURCHASE, 2018–2027 (USD MILLION)

TABLE 30 FRANCE: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY PLATFORM, 2018–2027 (USD MILLION)

TABLE 31 UK: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY PRODUCT, 2018–2027 (USD MILLION)

TABLE 32 UK: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY END USER, 2018–2027 (USD MILLION)

TABLE 33 UK: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY MODE OF PURCHASE, 2018–2027 (USD MILLION)

TABLE 34 UK: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY PLATFORM, 2018–2027 (USD MILLION)

TABLE 35 ITALY: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY PRODUCT, 2018–2027 (USD MILLION)

TABLE 36 ITALY: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY END USER2018–2027 (USD MILLION)

TABLE 37 ITALY: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY MODE OF PURCHASE, 2018–2027 (USD MILLION)

TABLE 38 ITALY: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY PLATFORM, 2018–2027 (USD MILLION)

TABLE 39 SPAIN: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY PRODUCT, 2018–2027 (USD MILLION)

TABLE 40 SPAIN: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY END USER, 2018–2027 (USD MILLION)

TABLE 41 SPAIN: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY MODE OF PURCHASE, 2018–2027 (USD MILLION)

TABLE 42 SPAIN: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BYPLATFORM2018–2027 (USD MILLION)

TABLE 43 REST OF EUROPE: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY PRODUCT, 2018–2027 (USD MILLION)

TABLE 44 REST OF EUROPE: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY END USER, 2018–2027 (USD MILLION)

TABLE 45 REST OF EUROPE: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY MODE OF PURCHASE, 2018–2027 (USD MILLION)

TABLE 46 REST OF EUROPE: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY PLATFORM, 2018–2027 (USD MILLION)

TABLE 47 ASIA-PACIFIC: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY PRODUCT, 2018–2027 (USD MILLION)

TABLE 48 ASIA-PACIFIC: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY END USER, 2018–2027 (USD MILLION)

TABLE 49 ASIA-PACIFIC: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY MODE OF PURCHASE, 2018–2027 (USD MILLION)

TABLE 50 ASIA-PACIFIC: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY PLATFORM, 2018–2027 (USD MILLION)

TABLE 51 CHINA: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY PRODUCT, 2018–2027 (USD MILLION)

TABLE 52 CHINA: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY END USER, 2018–2027 (USD MILLION)

TABLE 53 CHINA: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY MODE OF PURCHASE, 2018–2027 (USD MILLION)

TABLE 54 CHINA: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY PLATFORM, 2018–2027 (USD MILLION)

TABLE 55 INDIA: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY PRODUCT, 2018–2027 (USD MILLION)

TABLE 56 INDIA: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY END USER, 2018–2027 (USD MILLION)

TABLE 57 INDIA: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY MODE OF PURCHASE, 2018–2027 (USD MILLION)

TABLE 58 INDIA: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY PLATFORM, 2018–2027 (USD MILLION)

TABLE 59 JAPAN: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY PRODUCT, 2018–2027 (USD MILLION)

TABLE 60 JAPAN: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY END USER, 2018–2027 (USD MILLION)

TABLE 61 JAPAN: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY MODE OF PURCHASE, 2018–2027 (USD MILLION)

TABLE 62 JAPAN: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY PLATFORM, 2018–2027 (USD MILLION)

TABLE 63 SOUTH KOREA: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY PRODUCT, 2018–2027 (USD MILLION)

TABLE 64 SOUTH KOREA: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY END USER, 2018–2027 (USD MILLION)

TABLE 65 SOUTH KOREA: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY MODE OF PURCHASE, 2018–2027 (USD MILLION)

TABLE 66 SOUTH KOREA: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY PLATFORM, 2018–2027 (USD MILLION)

TABLE 67 AUSTRALIA: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY PRODUCT, 2018–2027 (USD MILLION)

TABLE 68 AUSTRALIA: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY END USER, 2018–2027 (USD MILLION)

TABLE 69 AUSTRALIA: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY MODE OF PURCHASE, 2018–2027 (USD MILLION)

TABLE 70 AUSTRALIA: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY PLATFORM, 2018–2027 (USD MILLION)

TABLE 71 REST OF ASIA-PACIFIC: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY PRODUCT, 2018–2027 (USD MILLION)

TABLE 72 REST OF ASIA-PACIFIC: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY END USER, 2018–2027 (USD MILLION)

TABLE 73 REST OF ASIA-PACIFIC: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY MODE OF PURCHASE, 2018–2027 (USD MILLION)

TABLE 74 REST OF ASIA-PACIFIC: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY PLATFORM, 2018–2027 (USD MILLION)

TABLE 75 REST OF WORLD: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY PRODUCT, 2018–2027 (USD MILLION)

TABLE 76 REST OF WORLD: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY END USER, 2018–2027 (USD MILLION)

TABLE 77 REST OF WORLD: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY MODE OF PURCHASE, 2018–2027 (USD MILLION)

TABLE 78 REST OF WORLD: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY PLATFORM, 2018–2027 (USD MILLION)

TABLE 79 MIDDLE EAST: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY PRODUCT, 2018–2027 (USD MILLION)

TABLE 80 MIDDLE EAST: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY END USER, 2018–2027 (USD MILLION)

TABLE 81 MIDDLE EAST: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY MODE OF PURCHASE, 2018–2027 (USD MILLION)

TABLE 82 MIDDLE EAST: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY PLATFORM, 2018–2027 (USD MILLION)

TABLE 83 AFRICA: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY PRODUCT, 2018–2027 (USD MILLION)

TABLE 84 AFRICA: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY END USER, 2018–2027 (USD MILLION)

TABLE 85 AFRICA: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY MODE OF PURCHASE, 2018–2027 (USD MILLION)

TABLE 86 AFRICA: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY PLATFORM, 2018–2027 (USD MILLION)

TABLE 87 LATIN AMERICA: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY PRODUCT, 2018–2027 (USD MILLION)

TABLE 88 LATIN AMERICA: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY END USER, 2018–2027 (USD MILLION)

TABLE 89 LATIN AMERICA: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY MODE OF PURCHASE, 2018–2027 (USD MILLION)

TABLE 90 LATIN AMERICA: POINT OF CARE DIAGNOSTICS/TESTING MARKET, BY PLATFORM, 2018–2027 (USD MILLION)

LIST OF FIGURES

FIGURE 1 RESEARCH PROCESS

FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL POINT OF CAREDIAGNOSTICS/TESTING MARKET

FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL POINT OF CARE DIAGNOSTICS/TESTING MARKET

FIGURE 4 GLOBAL POINT OF CARE DIAGNOSTICS/TESTING MARKET SHARE, BY PRODUCT, 2020 (%)

FIGURE 5 GLOBAL POINT OF CARE DIAGNOSTICS/TESTING MARKET SHARE, BY END USER, 2020 (%)

FIGURE 6 GLOBAL POINT OF CARE DIAGNOSTICS/TESTING MARKET SHARE, BY MODE OF PURCHASE, 2020 (%)

FIGURE 7 GLOBAL POINT OF CARE DIAGNOSTICS/TESTING MARKET SHARE, BY PLATFORM, 2020 (%)

FIGURE 8 GLOBAL POINT OF CARE DIAGNOSTICS/TESTING MARKET SHARE, BY REGION, 2020 (%)

FIGURE 9 NORTH AMERICAPOINT OF CARE DIAGNOSTICS/TESTING MARKET SHARE, BY PRODUCT, 2020 (%)

FIGURE 10 NORTH AMERICAPOINT OF CARE DIAGNOSTICS/TESTING MARKET SHARE, BY END USER, 2020 (%)

FIGURE 11 NORTH AMERICAPOINT OF CARE DIAGNOSTICS/TESTING MARKET SHARE, BY MODE OF PURCHASE, 2020 (%)

FIGURE 12 NORTH AMERICAPOINT OF CARE DIAGNOSTICS/TESTING MARKET SHARE, BY PLATFORM, 2020 (%)

FIGURE 13 EUROPEPOINT OF CARE DIAGNOSTICS/TESTING MARKET SHARE, BY PRODUCT, 2020 (%)

FIGURE 14 EUROPEPOINT OF CARE DIAGNOSTICS/TESTING MARKET SHARE, BY END USER, 2020 (%)

FIGURE 15 EUROPEPOINT OF CARE DIAGNOSTICS/TESTING MARKET SHARE, BY MODE OF PURCHASE, 2020 (%)

FIGURE 16 EUROPEPOINT OF CARE DIAGNOSTICS/TESTING MARKET SHARE, BY PLATFORM, 2020 (%)

FIGURE 17 ASIA-PACIFICPOINT OF CARE DIAGNOSTICS/TESTING MARKET SHARE, BY PRODUCT, 2020 (%)

FIGURE 18 ASIA-PACIFICPOINT OF CARE DIAGNOSTICS/TESTING MARKET SHARE, BY END USER, 2020 (%)

FIGURE 19 ASIA-PACIFICPOINT OF CARE DIAGNOSTICS/TESTING MARKET SHARE, BY MODE OF PURCHASE, 2020 (%)

FIGURE 20 ASIA-PACIFICPOINT OF CARE DIAGNOSTICS/TESTING MARKET SHARE, BY PLATFORM, 2020 (%)

FIGURE 21 REST OF THE WORLDPOINT OF CARE DIAGNOSTICS/TESTING MARKET SHARE, BY PRODUCT, 2020 (%)

FIGURE 22 REST OF THE WORLD POINT OF CARE DIAGNOSTICS/TESTING MARKET SHARE, BY END USER, 2020 (%)

FIGURE 23 REST OF THE WORLDPOINT OF CARE DIAGNOSTICS/TESTING MARKET SHARE, BY MODE OF PURCHASE, 2020 (%)

FIGURE 24 REST OF THE WORLD POINT OF CARE DIAGNOSTICS/TESTING MARKET SHARE, BY PLATFORM, 2020 (%)

FIGURE 25 ABBOTT LABORATORIES .: KEY FINANCIALS

FIGURE 26 ABBOTT LABORATORIES : SEGMENTAL REVENUE

FIGURE 27 ABBOTT LABORATORIES : REGIONAL REVENUE

FIGURE 28 SIEMENS HEALTHINEERS GMBH : KEY FINANCIALS

FIGURE 29 SIEMENS HEALTHINEERS GMBH : SEGMENTAL REVENUE

FIGURE 30 SIEMENS HEALTHINEERS GMBH : REGIONAL REVENUE

FIGURE 31 CHEMBIO DIAGNOSTICS, INC. : KEY FINANCIALS

FIGURE 32 CHEMBIO DIAGNOSTICS, INC. : SEGMENTAL REVENUE

FIGURE 33 CHEMBIO DIAGNOSTICS, INC. : REGIONAL REVENUE

FIGURE 34 F. HOFFMANN-LA ROCHE LTD.: KEY FINANCIALS

FIGURE 35 F. HOFFMANN-LA ROCHE LTD.: SEGMENTAL REVENUE

FIGURE 36 F. HOFFMANN-LA ROCHE LTD.: REGIONAL REVENUE

FIGURE 37 JOHNSON & JOHNSON SERVICES, INC. : KEY FINANCIALS

FIGURE 38 JOHNSON & JOHNSON SERVICES, INC. : SEGMENTAL REVENUE

FIGURE 39 JOHNSON & JOHNSON SERVICES, INC. : REGIONAL REVENUE

FIGURE 40 BECTON, DICKINSON AND COMPANY : KEY FINANCIALS

FIGURE 41 BECTON, DICKINSON AND COMPANY : SEGMENTAL REVENUE

FIGURE 42 BECTON, DICKINSON AND COMPANY : REGIONAL REVENUE

FIGURE 43 DANAHER CORPORATION : KEY FINANCIALS

FIGURE 44 DANAHER CORPORATION : SEGMENTAL REVENUE

FIGURE 45 DANAHER CORPORATION : REGIONAL REVENUE

FIGURE 46 PTS DIAGNOSTICS: KEY FINANCIALS

FIGURE 47 PTS DIAGNOSTICS: SEGMENTAL REVENUE

FIGURE 48 PTS DIAGNOSTICS: REGIONAL REVENUE

FIGURE 49 NOVA BIOMEDICAL : KEY FINANCIALS

FIGURE 50 NOVA BIOMEDICAL : SEGMENTAL REVENUE

FIGURE 51 NOVA BIOMEDICAL : REGIONAL REVENUE

FIGURE 52 QUIDEL CORPORATION : KEY FINANCIALS

FIGURE 53 QUIDEL CORPORATION : SEGMENTAL REVENUE

FIGURE 54 QUIDEL CORPORATION : REGIONAL REVENUE

FIGURE 55 SEKISUI DIAGNOSTICS : KEY FINANCIALS

FIGURE 56 SEKISUI DIAGNOSTICS : SEGMENTAL REVENUE

FIGURE 57 SEKISUI DIAGNOSTICS : REGIONAL REVENUE

FIGURE 58 TRINITY BIOTECH : KEY FINANCIALS

FIGURE 59 TRINITY BIOTECH : SEGMENTAL REVENUE

FIGURE 60 TRINITY BIOTECH : REGIONAL REVENUE

FIGURE 61 ACCUBIOTECH CO., LTD.: KEY FINANCIALS

FIGURE 62 ACCUBIOTECH CO., LTD.: SEGMENTAL REVENUE

FIGURE 63 ACCUBIOTECH CO., LTD.: REGIONAL REVENUE

FIGURE 64 INSTRUMENTATION LABORATORY COMPANY (WERFEN): KEY FINANCIALS

FIGURE 65 INSTRUMENTATION LABORATORY COMPANY (WERFEN): SEGMENTAL REVENUE

FIGURE 66 INSTRUMENTATION LABORATORY COMPANY (WERFEN): REGIONAL REVENUE

FIGURE 67 EKF DIAGNOSTICS HOLDINGS PLC: KEY FINANCIALS

FIGURE 68 EKF DIAGNOSTICS HOLDINGS PLC: SEGMENTAL REVENUE

FIGURE 69 EKF DIAGNOSTICS HOLDINGS PLC: REGIONAL REVENUE



This table of content is tentative and subject to change as the research progresses.

Please Note:  Financial details of company cannot be provided if the information of the company is not available in public domain and or reliable source.